---
schema_version: "secwatch.filing_event.v1"
accession: "0001297184-25-000054"
form_type: "8-K"
ticker: "AMPH"
cik: "0001297184"
company_name: "Amphastar Pharmaceuticals, Inc."
filed_at: "2025-09-18T23:59:59+00:00"
generated_at: "2026-05-17T06:12:44.960044+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Amphastar enters $2.8M R&D agreement with related-party Hanxin for AMP-107 cell banks

## Summary
- Agreement with Nanjing Hanxin to develop Recombinant Peptide Research Cell Banks (RCBs) for product candidate AMP-107.
- Total cost not to exceed ~$2.8M; initial payment ~$0.3M; payments in Chinese yuan.
- Hanxin majority-owned by CEO Jack Zhang, Chairman Mary Luo, and family; approved by independent audit committee.
- Term of three years; all title to RCBs and related IP will belong to Amphastar.

## SEC filing metadata
- accession: 0001297184-25-000054
- form_type: 8-K
- ticker: AMPH
- cik: 0001297184
- company_name: Amphastar Pharmaceuticals, Inc.
- filed_at: 2025-09-18T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000054/0001297184-25-000054-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1297184/000129718425000054/amph-20250915x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001297184-25-000054
- JSON: https://secwatch.observer/filing/0001297184-25-000054.json
- Plain text: https://secwatch.observer/filing/0001297184-25-000054.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.